(Q45867114)

17 December 2017

title

In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes (English)

1 reference

17 December 2017

author name string

Soltani N

1

1 reference

17 December 2017

Kumar M

2

1 reference

17 December 2017

Glinka Y

3

1 reference

17 December 2017

Prud'homme GJ

4

1 reference

17 December 2017

Wang Q

5

1 reference

17 December 2017

publication date

5 April 2007

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

12

1 reference

17 December 2017

page(s)

981-988

1 reference

17 December 2017

Life and death of the pancreatic beta cells

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Type 1 1/2 diabetes: myth or reality?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Immunotherapy for the prevention and treatment of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

beta-Cell death during progression to diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Pancreatic beta-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Glucagon-like peptide 1(GLP-1) in biology and pathology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Biological actions and therapeutic potential of the glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Challenges and strategies for moving patients to injectable medications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

TNFα as Therapeutic Target: New Drugs, More Applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Formatting antibody fragments to mediate specific therapeutic functions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPgammaS binding responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

G-protein-coupled receptor oligomerization and its potential for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Interferon gamma receptor extracellular domain expressed as IgG fusion protein in Chinese hamster ovary cells. Purification, biochemical characterization, and stoichiometry of binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Immunobiology of the immature B cell: plasticity in the B-cell antigen receptor-induced response fine tunes negative selection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Altering immune tolerance therapeutically: the power of negative thinking

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Multidose streptozotocin induction of diabetes in BALB/c mice induces a dominant oxidative macrophage and a conversion of TH1 to TH2 phenotypes during disease progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Effector mechanisms in low-dose streptozotocin-induced diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

The NOD mouse: a model of immune dysregulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

An improved plasmid DNA expression vector for direct injection into skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Gene therapy of streptozotocin-induced diabetes by intramuscular delivery of modified preproinsulin genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302944

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302944

1 reference

17 December 2017

Dimensions Publication ID

1039455603

0 references

1 reference

17 December 2017